주간 브리프 목록 Vol. 1 · 2026-06-22

글로벌 규제 모니터
2026년 6월 4주차 브리프

검색 기간 2026-06-15 ~ 2026-06-22 발행일 2026-06-22 수집 36건 · 카드 36 Evidence A 15 · B 21 · C 0

글로벌 34장

💊 합성의약품
[FDA 483 실사 관찰 · FDA]Central Alabama Veterans Health Care System
Evidence BFDASignal High · T3💊 합성의약품483
발행일2026-05-27
문서번호fda483-192438
제조소/업체Central Alabama Veterans Health Care System · FEI 1073935
시설 · 유형Producer of Sterile Drug Products · 483
실사일04/16/2026
[FDA 483 실사 관찰 · FDA]Intas Pharmaceutical Limited
Evidence BFDASignal High · T3💊 합성의약품483
발행일2026-05-26
문서번호fda483-192689
제조소/업체Intas Pharmaceutical Limited · FEI 3005890633
시설 · 유형Drug Product Manufacturer · 483
실사일09/17/2025
[FDA 483 실사 관찰 · FDA]Dabur India Limited
Evidence BFDASignal High · T3💊 합성의약품483
발행일2026-05-26
문서번호fda483-192690
제조소/업체Dabur India Limited · FEI 3001413302
시설 · 유형OTC Drug Manufacturer · 483
실사일01/16/2026
▫️ 기타
[Warning Letter · FDA]Pharmathen International S.A.
Evidence BFDASignal High · T3▫️ 기타CGMP
발행일2026-06-16
문서번호d1e41608f7ba
업체/제조소Pharmathen International S.A.
발행 부서/일자Center for Drug Evaluation and Research (CDER) · 05/27/2026
[FDA 483 실사 관찰 · FDA]BPI Labs, LLC
Evidence BFDASignal High · T3▫️ 기타483
발행일2026-05-27
문서번호fda483-192439
제조소/업체BPI Labs, LLC · FEI 3015156709
시설 · 유형Outsourcing Facility · 483
실사일04/17/2026
[FDA 483 실사 관찰 · FDA]Wells Pharma of Houston LLC
Evidence BFDASignal High · T3▫️ 기타483
발행일2026-05-27
문서번호fda483-192443
제조소/업체Wells Pharma of Houston LLC · FEI 3016710931
시설 · 유형Outsourcing Facility · 483
실사일04/13/2026
[규제 소식 · ECA]GDP Non-Compliance Report: Missed CAPA Timelines lead to Ref…
Evidence BECASignal Med · T2GMP News
발행일2026-06-18
문서번호4399b537ba30
발행기관ECA
주제GDP Non-Compliance Report: Missed CAPA Timelines lead to Refusal of GDP Certific…
[지침·안내서 · FDA]Agency Information Collection Activities; Submission for Off…
Evidence AFDASignal Med · T2Guidance
발행일2026-06-18
문서번호2026-12237
발행기관FDA
주제Agency Information Collection Activities; Submission for Office of Management an…
원문
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
[지침·안내서 · FDA]Agency Information Collection Activities; Submission for Off…
Evidence AFDASignal Med · T2Guidance
발행일2026-06-18
문서번호2026-12238
발행기관FDA
주제Agency Information Collection Activities; Submission for Office of Management an…
원문
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
[규제 소식 · ECA]FDA Warning Letter: Deficiencies in Incoming Component Testi…
Evidence BECASignal Med · T2GMP News
발행일2026-06-17
문서번호bfa2307d43e9
발행기관ECA
주제FDA Warning Letter: Deficiencies in Incoming Component Testing, Stability Progra…
[FDA 483 실사 관찰 · FDA]BlendHouse Portland LLC
Evidence BFDASignal Med · T2▫️ 기타483
발행일2026-06-11
문서번호fda483-192871
제조소/업체BlendHouse Portland LLC · FEI 3013670080
시설 · 유형Manufacturer · Establishment Inspection Report (EIR)
실사일01/23/2026
[FDA 483 실사 관찰 · FDA]BlendHouse Allerton LLC
Evidence BFDASignal Med · T2▫️ 기타483
발행일2026-06-11
문서번호fda483-192916
제조소/업체BlendHouse Allerton LLC · FEI 1921383
시설 · 유형Manufacturer · Establishment Inspection Report (EIR)
실사일01/22/2026
[지침·안내서 · FDA]Epizyme, Inc.
Evidence AFDASignal Low · T1Guidance
발행일2026-06-22
문서번호2026-12367
발행기관FDA
주제Epizyme, Inc.
원문
The Food and Drug Administration (FDA or Agency) is withdrawing approval of new drug application (NDA) for TAZVERIK (tazemetostat) tablet, 200 milligrams (mg), held by Epizyme, Inc., an Ipsen Company (Epizyme), 1 Main St., Cambridge, MA 02142.
[지침·안내서 · FDA]Medical Devices; Immunology and Microbiology Devices; Classi…
Evidence AFDASignal Low · T1Guidance
발행일2026-06-22
문서번호2026-12443
발행기관FDA
주제Medical Devices; Immunology and Microbiology Devices; Classification of the Simp…
원문
The Food and Drug Administration (FDA) is classifying the simple in vitro diagnostic device for the detection of secreted proteins from Bacillus species (spp.) in human clinical samples into class II (special controls).
[지침·안내서 · FDA]Medical Devices; Gastroenterology-Urology Devices; Classific…
Evidence AFDASignal Low · T1Guidance
발행일2026-06-22
문서번호2026-12444
발행기관FDA
주제Medical Devices; Gastroenterology-Urology Devices; Classification of the Endosco…
원문
The Food and Drug Administration (FDA) is classifying the endoscopic light-projecting measuring device into class II (special controls).
[지침·안내서 · FDA]Medical Devices; Gastroenterology-Urology Devices; Classific…
Evidence AFDASignal Low · T1Guidance
발행일2026-06-22
문서번호2026-12445
발행기관FDA
주제Medical Devices; Gastroenterology-Urology Devices; Classification of the Endosco…
원문
The Food and Drug Administration (FDA) is classifying the endoscopic traction device into class II (special controls).
[규제 소식 · EMA]Meeting highlights from the Committee for Veterinary Medicin…
Evidence BEMASignal Low · T1GMP News
발행일2026-06-19
문서번호a539f45fec9e
발행기관EMA
주제Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 1…
[규제 소식 · ECA]Questions and Answers from the ECA Webinar "GDP Update 2026"…
Evidence BECASignal Low · T1GMP News
발행일2026-06-18
문서번호1c4f028e2881
발행기관ECA
주제Questions and Answers from the ECA Webinar "GDP Update 2026" - Part 4
[규제 소식 · ECA]GDPA Participated as an Observer in the EMA GMDP-IWG Interes…
Evidence BECASignal Low · T1GMP News
발행일2026-06-18
문서번호ce1e12b61e37
발행기관ECA
주제GDPA Participated as an Observer in the EMA GMDP-IWG Interested Parties Meeting
[지침·안내서 · FDA]Advisory Committee; Science Board to the Food and Drug Admin…
Evidence AFDASignal Low · T1Guidance
발행일2026-06-18
문서번호2026-12235
발행기관FDA
주제Advisory Committee; Science Board to the Food and Drug Administration; Renewal
원문
The Food and Drug Administration (FDA) is announcing the renewal of the Science Board to the Food and Drug Administration by the Commissioner of Food and Drugs (the Commissioner).
[지침·안내서 · FDA]SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug A…
Evidence AFDASignal Low · T1Guidance
발행일2026-06-18
문서번호2026-12236
발행기관FDA
주제SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methy…
원문
The Food and Drug Administration (FDA or Agency) is withdrawing approval of abbreviated new drug application (ANDA) 202608 for Methylphenidate Hydrochloride (HCl) Extended-Release (ER) tablets, 27 milligrams (mg), 36 mg, and 54 mg, held by SpecGx LLC…
[지침·안내서 · FDA]Agency Information Collection Activities; Proposed Collectio…
Evidence AFDASignal Low · T1Guidance
발행일2026-06-18
문서번호2026-12239
발행기관FDA
주제Agency Information Collection Activities; Proposed Collection; Comment Request;…
원문
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency.
[지침·안내서 · FDA]Authorization of Emergency Use for Two Animal Drugs for the…
Evidence AFDASignal Low · T1Guidance
발행일2026-06-18
문서번호2026-12245
발행기관FDA
주제Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treat…
원문
The Food and Drug Administration (FDA or the Agency) is announcing the issuance of two Emergency Use Authorizations (EUA) (Authorization) under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for new animal products.
[규제 소식 · ECA]European GDP Association Developments January through April…
Evidence BECASignal Low · T1GMP News
발행일2026-06-17
문서번호92613444e102
발행기관ECA
주제European GDP Association Developments January through April 2026
[규제 소식 · ECA]FDA adopts updated ICH Q8/Q9/Q10 Questions & Answers (R5)
Evidence BECASignal Low · T1GMP News
발행일2026-06-17
문서번호c1adef04914d
발행기관ECA
주제FDA adopts updated ICH Q8/Q9/Q10 Questions & Answers (R5)
[규제 소식 · ECA]BioPhorum Publishes a Roadmap for QC Sample Test Execution
Evidence BECASignal Low · T1GMP News
발행일2026-06-17
문서번호e170a70f927c
발행기관ECA
주제BioPhorum Publishes a Roadmap for QC Sample Test Execution
[지침·안내서 · FDA]Medical Devices; Gastroenterology-Urology Devices; Classific…
Evidence AFDASignal Low · T1Guidance
발행일2026-06-17
문서번호2026-12165
발행기관FDA
주제Medical Devices; Gastroenterology-Urology Devices; Classification of the Ingesti…
원문
The Food and Drug Administration (FDA) is classifying the ingestible gastrointestinal blood detection capsule into class II (special controls).
[지침·안내서 · FDA]Medical Devices; Radiology Devices; Classification of the Ra…
Evidence AFDASignal Low · T1Guidance
발행일2026-06-17
문서번호2026-12166
발행기관FDA
주제Medical Devices; Radiology Devices; Classification of the Radiological Machine L…
원문
The Food and Drug Administration (FDA) is classifying the radiological machine learning-based quantitative imaging software with predetermined change control plan into class II (special controls).
[지침·안내서 · FDA]Andrew Jonathan Morgan: Final Debarment Order
Evidence AFDASignal Low · T1Guidance
발행일2026-06-17
문서번호2026-12167
발행기관FDA
주제Andrew Jonathan Morgan: Final Debarment Order
원문
The Food and Drug Administration (FDA or the Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Andrew Jonathan Morgan for a period of 5 years from importing or offering for import any drug into the United…
[Warning Letter · FDA]Roen Health, Inc. dba RoenRx
Evidence BFDASignal Low · T1CGMP
발행일2026-06-16
문서번호1c12afdcf673
업체/제조소Roen Health, Inc. dba RoenRx
발행 부서/일자Center for Drug Evaluation and Research (CDER) · 06/08/2026
[Warning Letter · FDA]OrderlyMeds LLC dba OrderlyMeds
Evidence BFDASignal Low · T1CGMP
발행일2026-06-16
문서번호4a58d2e02eb1
업체/제조소OrderlyMeds LLC dba OrderlyMeds
발행 부서/일자Center for Drug Evaluation and Research (CDER) · 06/08/2026
[Warning Letter · FDA]Joi and Blokes dba Joi + Blokes
Evidence BFDASignal Low · T1CGMP
발행일2026-06-16
문서번호f28938fbb3d2
업체/제조소Joi and Blokes dba Joi + Blokes
발행 부서/일자Center for Drug Evaluation and Research (CDER) · 06/08/2026
[규제 소식 · EMA]Questions and answers on the impact of Mutual Recognition Ag…
Evidence BEMASignal Low · T1GMP News
발행일2026-06-11
문서번호1bae7194b5bc
발행기관EMA
주제Questions and answers on the impact of Mutual Recognition Agreement (MRA) betwee…

국내 1장

[행정처분 · MFDS]경방신약(주)
Evidence AMFDSSignal High · T3💊 합성의약품행정처분
발행일2026-06-17
문서번호admin-2026004434
업체경방신약(주)
처분해당품목 제조업무정지 1개월(2026. 7. 1. ~ 2026. 7. 31.): 쎄파렉신캡슐(은교산), 소폐탕엑스과립(소청룡탕)
원문
○ 의약품 제조업자는 의약품을 제조하면서 제조관리기준서, 제품표준서 등에 따라 정확히 제조하여야 하고, 작성된 기준서 및 지시서를 준수하여야 하나, ‘쎄파렉신캡슐(은교산)’, ‘소폐탕엑스과립(소청룡탕)’에 대하여 다음과 같이 기준서를 준수하지 않은 사실이 있음 - 제조관리기준서 「원료 칭량 관리」(문서번호 PMN032, 승인일자 2025.
10.

Recall 1장

[Recall(HC) · Health Canada][HC] Lancora Tablets; Broken / partial tablets in blister pa…
Evidence AHealth CanadaSignal Med · T2💊 합성의약품Recall
발행일2026-06-16
문서번호hc-82222
업체원문 미기재
제품Lancora 5 mg tablet
ClassType III
원문
Product quality
AI 자동 생성 안내 · 본 자료는 1차 공식 자료를 바탕으로 AI가 자동 작성한 규제 정보 요약입니다. 사실 항목은 출처·원본을 병기해 추적 가능하나, 시사점·점검 항목은 AI 해석으로 공식 견해나 법적 자문이 아닙니다. 의사결정 전 반드시 원문을 확인하십시오. This digest is AI-generated from primary sources; interpretations are not official or legal advice — verify against the original before acting.